ArticlePloS one2025
Ex ante economic impact assessment of the 3R-gene potato in Kenya.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Potato late-blight disease is as a major constraint to potato production in Kenya. The use of fungicides to control the disease is limited by the practice of delaying application until the symptoms are visible, and inappropriate application rates and methods. Biotech crops, such as 3R-gene potato, are providing sustainable solutions to crop protection challenges in agriculture, but little is known about their social and economic potential in any country. To gain greater insights into the potential of 3R-gene potato in Kenya, this study evaluates the economic benefits of Asante, Shangi, and Tigoni potato varieties, which are resistant to late blight. Data from experts along the potato value chain and secondary sources are analyzed using the economic surplus model and a real options model. First, experts' opinions revealed that late-blight disease is responsible for 23% of production loss annually, and that 12% of the production costs are due to the use of fungicides to control late blight disease. Secondly, the study results suggest that the release of 3R-gene Shangi would generate the greatest economic benefits of KES 845.9 million (US$ 8.2 million) annually. The expected net benefits of 3R-gene Asante are KES 7.3 million (US$ 0.07 million) annually. 3R-gene Tigoni, with the lowest potential adoption rates, would be expected to realize a negative net of KES of -1.26 million (US$ -0.01 million) annually. Significant potential economic gains, which is expected to increase with better awareness of biotech crops, support the immediate release of 3R-gene Shangi in Kenya.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.